Denali Therapeutics' AVLAYAH, the first FDA-approved medicine using its Enzyme TransportVehicle technology to cross the blood-brain barrier, generated $3.6 million in revenue in its first full quarter while advancing a pipeline of brain-targeted therapies for neurodegenerative disease. The company's ability to deliver drugs across this critical barrier expands therapeutic options for conditions previously difficult to treat at the central nervous system level.
Key Points
- AVLAYAH generated $3.6M revenue Q2 2026, with guidance to triple by Q3
- Over 50% of US commercial payers now cover AVLAYAH; 14 state Medicaid programs included
- Two Alzheimer's candidates advanced using same blood-brain barrier technology in 2026
Longevity Analysis
The clinical validation of a technology platform that reliably crosses the blood-brain barrier represents a significant advance in addressing neurodegenerative conditions where therapeutic failure has historically stemmed from delivery rather than drug mechanism. This capability directly impacts the treatment landscape for Alzheimer's disease and other central nervous system pathologies where protein misfolding and neuroinflammation drive progressive cognitive decline. Denali's pipeline demonstrates that once a delivery barrier is solved, the focus shifts to identifying the correct molecular targets—a distinction that clarifies why platform success does not guarantee clinical efficacy for every candidate, as evidenced by the discontinuation of DNL151 in idiopathic Parkinson's disease despite mechanistic validation in genetically defined subsets.
Original published by Longevity.Technology, by Kyle Umipig.